☰

Anocca AB

From discovery engine to clinical manufacturer

Industry
Cell Therapy (TCR-T)
Headquarters
Södertälje, Sweden
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Anocca AB's published strategy and is not endorsed by, or produced in cooperation with, Anocca AB. Company website

Strategic priorities

Anocca is moving from a T-cell biology discovery engine to a clinical-stage manufacturer. The company's lead programme, VIDAR-1, is a multi-asset umbrella trial testing several autologous TCR-T candidates in advanced pancreatic cancer under a single EMA protocol — the first clinical study of non-viral gene-edited TCR-T therapy in Europe. The first clinical trial authorisation was announced in 2025, with the Phase I/II running across eight university hospitals in Sweden, Germany, Denmark and the Netherlands.

Manufacturing sits on the Södertälje campus, a former AstraZeneca research facility covering about 8,500 square metres with a 5,000 square metre GMP suite for autologous TCR-T production. The repurposed site brings high-quality bioprocessing hardware with it, including chillers, HVAC and facility systems originally specified for central-nervous-system research rather than cell therapy, which now have to feed data into AnoccaOS, the company's proprietary digital backbone.

The platform side of the business is built around AnoccaOS, eAPC and eTPC discovery systems, and a stated ambition to build foundational AI models of T-cell biology. On the manufacturing side, the day-to-day question is how to keep a multi-asset, multi-site, multi-country operation inspection-ready while every new bioreactor, scale or pump plugs into the same data backbone without rebuilding the integration each time.

Capital has followed the roadmap: a SEK 400 million Series B in 2021, €25 million venture debt from the European Investment Bank in 2022, a SEK 400 million equity round in 2023, and a SEK 440 million clinical round in August 2025. Investors include Swedbank Robur, AMF, Mellby Gård and Danske Bank. The funding pattern tracks a company moving money from discovery tooling into operations and clinical execution.

Challenges we see

  • Operations Manufacturing

    Tracking patient samples across eight hospitals and one factory

    The VIDAR-1 trial collects patient T-cells via leukapheresis at eight distributed hospital sites across four countries, then ships cryopreserved samples to Södertälje for editing and returns the engineered product to the same hospital. The first clinical trial authorisation was announced in 2025.

    Where chain-of-custody and temperature data live in different hospital and courier systems, the practical question for the manufacturing team is how to keep one continuous record of a sample from collection to infusion, with deviations surfaced in time to act.

  • Digital Integration

    Making a repurposed AstraZeneca site feed a cell-therapy data model

    The Södertälje campus occupies a former AstraZeneca research facility with pre-existing high-tech infrastructure including facility management systems, chillers and HVAC controls originally specified for CNS research rather than cell therapy.

    Equipment selected for a different product is now part of a tighter regulatory envelope, so the data those systems produce has to reach the same model the new bioreactors report to, even when the underlying controllers speak different protocols.

  • Digital Integration

    Adding new bioreactors and pumps without rewriting the integration layer

    As Anocca introduces new bioreactors, scales and pumps into the GMP facility, each must connect to the proprietary AnoccaOS platform, which was designed for T-cell biology modelling rather than for orchestrating a manufacturing floor.

    When every new device needs its own integration code, the engineering cost of a routine hardware change starts to sit on the critical path of a multi-asset clinical programme, and that cost grows with the number of devices rather than with the value of the change.

  • Compliance Regulatory

    Running a multi-product trial from a single regulatory record

    VIDAR-1 is a multi-product umbrella trial testing several TCR-T candidates simultaneously under one EMA protocol — the first clinical study of non-viral gene-edited TCR-T therapy in Europe.

    A single protocol covering multiple products has to keep each product's regulatory, quality and traceability story distinct while sharing the same manufacturing and clinical evidence, which pushes the document model past what a conventional LIMS (Laboratory Information Management System) is asked to hold.

  • Compliance Regulatory

    Securing clinical and genomic data across borders

    Clinical operations span Sweden, Germany, Denmark and the Netherlands and handle sensitive patient genomic data, with manufacturing OT subject to NIS2 cybersecurity obligations and GAMP5 validated-software requirements.

    Where discovery labs and clinical production share a network footprint but face different regulatory regimes, the design question is how to keep clinical and genomic data reachable for legitimate use while keeping discovery systems isolated from the production estate.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Tracing patient samples from hospital to manufacturing and back

    Chain-of-custody, temperature and manufacturing status for VIDAR-1 samples currently sit in the systems of different hospitals, couriers and the central facility, with no single integrated view across the eight clinical sites and Södertälje.

    A single platform that captures collection, shipping, manufacturing and return milestones for each sample — with temperature deviations flagged as they happen — gives the clinical coordinator, the manufacturing team and the regulator the same record rather than three partial ones.

    • Anocca press release, First In-Human Trial Authorisation, 2025
    • Anocca Deep Research, sections 2.1, 4.3

  2. Reaching NIS2 and GAMP5 audit-readiness across production and discovery

    Clinical operations span four countries and handle sensitive patient genomic data, while manufacturing OT carries NIS2 and GAMP5 obligations and legacy PLCs and SCADA systems from the former AstraZeneca site remain in scope.

    A Zero Trust model with identity-based access, network segmentation between discovery and production, and continuous compliance evidence turns the next regulatory inspection from a document-reconstruction exercise into a system query.

    • Anocca Deep Research, sections 2.3, 4.3
    • EU NIS2 directive scope as applied to manufacturing OT

  3. Standardising equipment integration with MTP

    Each new bioreactor, scale or pump added to the GMP facility requires custom integration with AnoccaOS, which was designed for biology modelling rather than manufacturing orchestration.

    An MTP (Module Type Package) layer lets new equipment describe its own services against a standard interface, so integration becomes a configuration task and the underlying engineering effort stays proportional to the value of the change.

    • Anocca Deep Research, section 2.2
    • MTP standard reference (NAMUR VDI/VDE 2658)

  4. Watching bioreactors continuously rather than by operator eye

    Critical quality attributes in bioreactor operations are still read largely by operator visual checks, leaving slow reaction times to foam formation, contamination risk and the loss of a patient-specific batch.

    A non-invasive camera-based foam and anomaly monitor that drives an antifoam dosing loop in software gives 24/7 coverage without touching the biological product contact surfaces, and adds an evidence stream to the batch record.

    • Anocca Deep Research, section 4.1
    • Anocca website, Our Platform and Our Software sections

  5. Wiring the legacy facility systems into the same data backbone

    The Södertälje site's facility management, chillers and HVAC controls were specified for CNS research and use protocols that do not connect directly to AnoccaOS.

    Retrofitting these systems with a protocol-translation layer feeds their operating data into the same time-series model the new bioreactors report to, so the GMP environment is described by the same evidence chain as the cells inside it.

    • Anocca Deep Research, section 2.1
    • Anocca Södertälje campus site description

What we'd propose

  • Enterprise AI

    Vein-to-vein sample and process tracking platform

    A platform that captures chain-of-custody, temperature, manufacturing and return milestones for each VIDAR-1 sample across the eight clinical sites and the Södertälje facility, with deviations flagged as they happen.

    • Multi-site sample tracking

      One record per sample

      Capture leukapheresis, cryopreservation, shipping, receipt, manufacturing and return milestones for each sample, with hospital, courier and manufacturing events written into the same record rather than reconciled from three.

    • Cold-chain monitoring

      Temperature excursions surfaced live

      Attach IoT temperature sensors to shipments and pair them with the sample record, so the manufacturing team sees a deviation against a specific batch while there is still time to act, and the regulatory file carries the same evidence.

    • Manufacturing status visibility

      Clinical coordinator sees the batch

      Connect the sample record to the GMP execution system so the clinical coordinator can see when editing has started, when it is released, and when the cryopreserved product is in transit back, without manual status emails.

    • The clinical coordinator, the manufacturing team and the regulator read the same record for each sample.
    • Temperature and chain-of-custody deviations are flagged while a batch is still recoverable.
    • Manual coordination between hospitals, couriers and Södertälje falls out of the release path.

    We've done this before

    See how we do Enterprise AI
  • Enterprise AI

    Zero Trust architecture and NIS2 readiness for production and discovery

    An identity-based access model, network segmentation between discovery and clinical production, and continuous compliance evidence designed for NIS2 and GAMP5 obligations, applied to the Södertälje OT environment and the multi-country clinical data flow.

    • Identity-based access

      Never trust, always verify

      Replace shared service accounts with per-user and per-service identities, multi-factor authentication and short-lived credentials, so that a leaked password does not open a path from one environment to another.

    • OT network segmentation

      Discovery and production kept apart

      Segment the Södertälje network into zones and conduits aligned to IEC 62443, separating discovery lab traffic, GMP production traffic and clinical data ingestion, and constraining what can move between them.

    • Continuous compliance evidence

      Audit-ready on demand

      Generate the evidence for NIS2 and GAMP5 controls continuously from the systems that enforce them — access events, segmentation checks, software validation status — so an inspection starts from a dashboard rather than a binder.

    • An inspection looks at a dashboard rather than a reconstructed document set.
    • Discovery and clinical production can be operated by the same organisation without sharing a network trust boundary.
    • Software validation evidence stays current with the system instead of lagging behind a release.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    MTP layer over AnoccaOS for plug-and-produce equipment

    An MTP-based integration layer that lets new bioreactors, scales, pumps and analytical instruments describe their services against a standard interface, so adding equipment becomes a configuration task rather than a custom-coding project.

    • MTP module library

      Standard interfaces for new devices

      Maintain an internal library of MTP-compliant service descriptions for the equipment categories Anocca buys most often — bioreactors, scales, pumps, analytical instruments — so a new device is integrated by selecting and configuring a module rather than writing code.

    • Process orchestration layer

      One scheduler over many modules

      Build a Process Orchestration Layer (POL) on top of AnoccaOS that talks to MTP-enabled equipment through the standard service interface, so the manufacturing schedule is written once and the modules carry it out without per-device translation.

    • Vendor-agnostic procurement

      Best-of-breed without lock-in

      Allow Anocca to choose equipment on performance and cost, because every device on the shop floor speaks the same MTP contract with the orchestration layer and the data backbone.

    • The engineering cost of adding a device stays proportional to the value of the change.
    • Multi-asset trials can reconfigure the line without rebuilding integrations.
    • The data backbone receives the same shape of record from every new machine.

    We've done this before

    See how we do Digital CDMO
  • Digital Lab

    Computer-vision bioreactor monitoring and foam control

    A camera-based monitoring system that detects foam and other visual anomalies in bioreactors in real time and drives an antifoam dosing loop, with the resulting evidence written into the batch record.

    • Foam detection model

      Continuous visual coverage

      Run a vision model on an external camera stream that watches the bioreactor headspace and flags slow-rising and flash-foam conditions against the current operating envelope, without modifying the product-contact surfaces.

    • Adaptive antifoam dosing

      Dosing driven by the model

      Drive the antifoam dosing pump from the foam signal using configurable interval, vector or PWM modes, so dosing responds to the foam behaviour rather than to a fixed schedule and the antifoam consumed per batch stays minimal.

    • Batch record evidence

      Images and signals captured as data

      Write the foam signal, dosing events and selected snapshots into the batch record with their own audit trail, so a contamination or process-deviation investigation starts from a continuous record rather than a reconstructed one.

    • Foam and contamination risk are addressed while the batch is still recoverable.
    • Antifoam consumption drops because dosing follows the foam signal rather than a fixed schedule.
    • Process evidence is generated by the line rather than compiled for review.

    We've done this before

    See how we do Digital Lab
  • Agents

    Narrow AI agents for VIDAR-1 regulatory and batch documents

    Reviewable agents that take the recurring document work for a multi-asset trial: drafting IND/CTA-equivalent and EMA submissions from source records, generating batch-record summaries, and finding every controlled document a standards or protocol change touches, with a named reviewer approving each output.

    • Drafting from source records

      First drafts from system data

      Generate the first draft of a regulatory submission, batch-record summary or deviation write-up from the underlying manufacturing, clinical and quality records, so the author edits and judges rather than assembles.

    • Template and completeness checking

      Gaps found before review

      Check a submitted document against the trial's template and the site's checklist, returning missing or inconsistent sections before it enters the human review queue.

    • Change-impact search across the document set

      Which documents a protocol change touches

      When an EMA protocol, a release specification or a manufacturing change is updated, retrieve every controlled document that references it across the multi-asset trial and rank them by how directly they are affected, so the update scope is known on day one.

    • The same document work that scales with the number of trial products stops scaling with headcount.
    • Review queues move faster because documents arrive complete and pre-checked.
    • Every output is traceable to the source records it came from and signed off by a named reviewer.

    We've done this before

    See how we do Agents

Where QB Systems fits

Alongside our services we build QB Systems, hardware and software for bioprocess control. QB Systems is a product brand of A4BEE Sp. z o.o.

Applications
Bioreactors

Software-defined control for a bioreactor — a new QB vessel, an upgrade to one you have, or a retrofit of the existing PLC.

Automated sampling

Automated sampling from 4–18 sources, aseptic-capable and up to 72 hours unattended. Works with any vendor's bioreactor.

Buffer & media preparation

Automated preparation of growth media and process buffers, so a recipe runs the same way every time without fixed infrastructure.

Deployment
Retrofit

Existing equipment keeps running; QB takes over the PLC, or reads from it without touching control.

Scale
Benchtop (1–8 L)

Glass vessels with the complete hardware and software stack. This is the core range for development work.

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Anocca AB's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Sample data integration 42 → 82
AnoccaOS is strong on T-cell biology modelling, but vein-to-vein data for VIDAR-1 currently sits across hospital, courier and manufacturing systems that are not unified into one record per sample.
Floor automation 48 → 80
Discovery automation is high through eAPC and eTPC; manufacturing still depends on operator visual checks for foam and on custom integration for new equipment.
Real-time visibility across sites 32 → 78
Multi-site clinical logistics have no integrated digital twin today; manufacturing status reaches the clinical coordinator manually rather than via the same record the regulator would read.
Equipment to enterprise connectivity 38 → 80
Legacy facility systems from the former AstraZeneca site use protocols that do not connect directly to AnoccaOS, and each new bioreactor still requires its own integration code.
Cybersecurity posture 46 → 86
Multi-country clinical and genomic data handling plus NIS2 and GAMP5 obligations place a higher bar than the current perimeter-based setup can meet; identity, segmentation and continuous evidence need to be put in place.
Regulatory and quality documentation 55 → 88
A multi-product umbrella trial under one EMA protocol places repeated regulatory, batch and quality document work on a small team; the document model is ahead of the document assembly process.

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Anocca AB, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].